Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2017’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)

The report reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hospital Acquired Pneumonia (HAP) therapeutics and enlists all their major and minor projects

The report assesses Hospital Acquired Pneumonia (HAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achaogen Inc

Adenium Biotech ApS

Aridis Pharmaceuticals LLC

AstraZeneca Plc

Bayer AG

Cardeas Pharma Corp

Destiny Pharma Ltd

Dong-A Socio Holdings Co Ltd

Lakewood-Amedex Inc

MedImmune LLC

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Motif Bio Plc

Nabriva Therapeutics AG

Polyphor Ltd

Sealife PHARMA GMBH

Shionogi & Co Ltd

Tetraphase Pharmaceuticals Inc

TGV-Inhalonix Inc

The Medicines Company

Theravance Biopharma Inc

Wockhardt Ltd

Zavante Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hospital Acquired Pneumonia (HAP) - Overview

Hospital Acquired Pneumonia (HAP) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development

Achaogen Inc

Adenium Biotech ApS

Aridis Pharmaceuticals LLC

AstraZeneca Plc

Bayer AG

Cardeas Pharma Corp

Destiny Pharma Ltd

Dong-A Socio Holdings Co Ltd

Lakewood-Amedex Inc

MedImmune LLC

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Motif Bio Plc

Nabriva Therapeutics AG

Polyphor Ltd

Sealife PHARMA GMBH

Shionogi & Co Ltd

Tetraphase Pharmaceuticals Inc

TGV-Inhalonix Inc

The Medicines Company

Theravance Biopharma Inc

Wockhardt Ltd

Zavante Therapeutics Inc

Hospital Acquired Pneumonia (HAP) - Drug Profiles

(amikacin sulfate + fosfomycin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(avibactam + ceftazidime) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(avibactam sodium + aztreonam lysine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ceftolozane sulfate + tazobactam sodium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(cilastatin sodium + imipenem + relebactam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(meropenem+ vaborbactam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AA-139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aerucin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alalevonadifloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amikacin sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbekacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cefepime + zidebactam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cefiderocol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

delafloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBX-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eravacycline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exeporfinium chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosfomycin tromethamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iclaprim mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lefamulin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Levonadifloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-3902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nu-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nu-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Panaecin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

panobacumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plazomicin sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

POL-7001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Qn-2251 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLP-0905 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

suvratoxumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tedizolid phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

telavancin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tosatoxumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Viritron VDX - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hospital Acquired Pneumonia (HAP) - Dormant Projects

Hospital Acquired Pneumonia (HAP) - Discontinued Products

Hospital Acquired Pneumonia (HAP) - Product Development Milestones

Featured News & Press Releases

Oct 31, 2016: New Data On Iclaprim Released At Idweek 2016; Iclaprim Shown To Be Highly Potent Against SSSI And HABP Clinical Isolates

Oct 31, 2016: Theravance Biopharma Presents Interim Data from Ongoing Telavancin Observational Use Registry (TOUR) at IDWeek 2016

Jul 21, 2016: AstraZeneca's antibiotic Zavicefta met primary endpoints in Phase III trial for treatment of hospital-acquired pneumonia

Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections

Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections

Jun 20, 2016: Results of Phase 2 Study of Merck's Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe

May 16, 2016: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA

May 16, 2016: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA

May 11, 2016: Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference

May 11, 2016: Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference

Apr 11, 2016: VIBATIV (Telavancin) Shows Greater In Vitro Potency Against Difficult-to-Treat Pathogens Causing Hospital-Acquired Bacterial Pneumonia, Including MRSA, Compared to Alternative Antibiotic Treatments

Apr 04, 2016: Theravance Biopharma to Present New Data Demonstrating Potent in vitro Activity for VIBATIV (telavancin) Against Difficult-to-Treat Infections, Including MRSA, at 2016 ECCMID Conference

Feb 26, 2016: Pendopharm Launches Vibativ In Canada

Feb 26, 2016: Pendopharm Launches Vibativ In Canada

Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Achaogen Inc, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Adenium Biotech ApS, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Aridis Pharmaceuticals LLC, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by AstraZeneca Plc, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Bayer AG, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Cardeas Pharma Corp, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Destiny Pharma Ltd, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Lakewood-Amedex Inc, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by MedImmune LLC, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Meiji Seika Pharma Co Ltd, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Melinta Therapeutics Inc, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Merck & Co Inc, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Motif Bio Plc, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Nabriva Therapeutics AG, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Polyphor Ltd, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Sealife PHARMA GMBH, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Shionogi & Co Ltd, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by TGV-Inhalonix Inc, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by The Medicines Company, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Theravance Biopharma Inc, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Wockhardt Ltd, H1 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Zavante Therapeutics Inc, H1 2017

Hospital Acquired Pneumonia (HAP) – Dormant Projects, H1 2017

Hospital Acquired Pneumonia (HAP) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports